The traditional methods for universal drug discovery are notoriously laborious, slowing down scientific progress and maximizing the amount of resources needed for every research phase.
By employing a revolutionizing AI, machine learning framework ANYO Labs’ technology has the capacity to reduce drug discovery timelines significantly; potentially cutting years from the normative period. Providing tools to screen vast databases of compounds, efficiently navigate large chemical libraries and generate de novo molecules, ANYO Labs is combining industry-leading accuracy with cost-efficiency and general optimization of the entire research process.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
ANYO Labs help pharmaceutical companies streamline research and lead optimization to prospectively benefit universal healthcare. This means that ANYO Labs is working with various stakeholders within the pharmaceutical industry such as full stack drug development actors, early biotech companies looking to technologically accelerate or established CRO companies, who are looking to integrate new cost- and time efficient initiatives.
ANYO Labs is currently engaged with a number of companies throughout Europe, and is looking to expand their current client base to new markets.
The team behind ANYO Labs is composed of complementary experts of cutting-edge technology and methodologies within AI, machine learning and physical chemistry. Together, this diverse team demonstrates both the dedication and experience needed, to consistently ensure results of the highest quality.
Unique selling point
Powered by AI and machine learning ANYO Labs presents groundbreaking tools that significantly accelerates pharmaceutical research and development in terms of time, methodologies and funding.
Thanks to the East Asian region’s rapidly evolving tech landscape, ANYO Labs is excited to explore potential partnerships with local companies, and co-create innovative, pharmaceutical solutions. With established contact to various actors active in the region, ANYO Labs is hoping to expand and discover more opportunities of collaboration and partnership.
GET IN TOUCH WITH